Maxygen, (FRA:MYN) Debt-to-EBITDA : 0.00 (As of Mar. 2013)

View and export this data going back to . Start your Free Trial

What is Maxygen, Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Maxygen,'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2013 was €0.00 Mil. Maxygen,'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2013 was €0.00 Mil. Maxygen,'s annualized EBITDA for the quarter that ended in Mar. 2013 was €-6.60 Mil. Maxygen,'s annualized Debt-to-EBITDA for the quarter that ended in Mar. 2013 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Maxygen,'s Debt-to-EBITDA or its related term are showing as below:

FRA:MYN's Debt-to-EBITDA is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.325
* Ranked among companies with meaningful Debt-to-EBITDA only.

Maxygen, Debt-to-EBITDA Historical Data

The historical data trend for Maxygen,'s Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maxygen, Debt-to-EBITDA Chart

Maxygen, Annual Data

Trend

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Debt-to-EBITDA

Get a 7-Day Free Trial

Maxygen, Quarterly Data
	Jun08	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13
Debt-to-EBITDA	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Maxygen,'s Debt-to-EBITDA

For the Biotechnology subindustry, Maxygen,'s Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maxygen,'s Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maxygen,'s Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Maxygen,'s Debt-to-EBITDA falls into.

Maxygen, Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Maxygen,'s Debt-to-EBITDA for the fiscal year that ended in Dec. 2012 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	15.48
	=	0.00

Maxygen,'s annualized Debt-to-EBITDA for the quarter that ended in Mar. 2013 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0	+	0)	/	-6.6
	=	0.00

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2013) EBITDA data.

Maxygen, (FRA:MYN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Maxygen, Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Maxygen,'s Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Maxygen, (FRA:MYN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maxygen, Inc. (FRA:MYN) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Maxygen, Inc., is incorporated in Delaware. It is a biotechnology company. It discovers and develops improved next-generation protein pharmaceuticals for the treatment of disease and serious medical conditions. The Company's MAXY-G34 product candidate has been designed to be an improved next-generation pegylated, G-CSF for the treatment of chemotherapy-induced neutropenia. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The Company completed a Phase IIa clinical trial for its MAXY-G34 product candidate for the treatment of chemotherapy-induced neutropenia in breast cancer patients in which MAXY-G34 was safe and effective in reducing chemotherapy-induced neutropenia with no serious adverse events, drug-related grade 3 or 4 adverse events or immunogenicity reported in any patient receiving MAXY-G34. Adverse events were consistent with known side effects of G-CSF molecules. The Company is subject to regulation by the FDA and comparable regulatory agencies in foreign countries with respect to any development and commercialization of its MAXY-G34 product candidate or any other products it may acquire in the future.